Sotorasib led to clinical improvement in two patients with disabling vascular malformations driven by the KRAS mutation G12C.
The New England Journal of Medicine: Search Results in Hematology/Oncology
Brief Report: Sotorasib for Vascular Malformations Associated with KRAS G12C Mutation
